The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis

Vol.21 No.4

Rapid Communication

The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis

Authors

Ryoko Sakai^1,2 , Yukiko Komano^1,2 , Michi Tanaka^1,2 , Toshihiro Nanki^1,2 , Ryuji Koike^1,2,3 , Atsuo Nakajima⁴ , Tatsuya Atsumi⁵ , Shinsuke Yasuda⁵ , Yoshiya Tanaka⁶ , Kazuyoshi Saito⁶ , Shigeto Tohma⁷ , Takao Fujii⁸, Atsushi Ihata⁹, Naoto Tamura¹⁰, Atsushi Kawakami¹¹, Takahiko Sugihara¹², Satoshi Ito^13,14, Nobuyuki Miyasaka², Masayoshi Harigai^1,2,3

Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Bunkyo-ku, Yushima, Tokyo 113-8519, Japan
Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
Clinical Research Center, Tokyo Medical and Dental University Hospital Faculty of Medicine, Tokyo, Japan
Tokyo Metropolitan Police Hospital, Tokyo, Japan
Department of Internal Medicine II, Hokkaido University, Graduate School of Medicine, Sapporo, Japan
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan
Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan
Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Department of Internal Medicine and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
Division of Clinical Immunology, Doctoral Programs in Clinical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan
Department of Rheumatology, Niigata Rheumatic Center, Niigata, Japan

Received:

20 December 2010

Accepted:

17 January 2011

Published online:

11 February 2011

Full Text

PDF　(member's only)

Abstract

Without Abstract

Key words

Adverse drug events - Methotrexate - Rheumatoid arthritis - Risk - Safety